NutriDex

The Supplement Research Compendium
🧂

Sucralose

E955 · Splenda

The heat-stable, calorie-free chlorinated sugar in Splenda

Moderate evidence 🍬Sweeteners & Additives

✚ Updated · How we grade evidence

Evidence tier
Moderate
Research weight
Citations
14 verified / 14
Classification
Sweeteners & Additives
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.

What is Sucralose?

Sucralose (E955 · Splenda) is a sweetener or food additive used for zero-calorie sweetness (~600x sweeter than sucrose; contributes negligible energy). NutriDex grades the human evidence as Moderate. Sucralose (E955, sold as Splenda) is a chlorinated derivative of sucrose roughly 600 times sweeter than sugar, used as a zero-calorie, heat-stable sweetener in diet sodas, tabletop packets, baked goods, dairy, and "sugar-free" and pharmaceutical products. It is approved as a food additive worldwide; the FDA (1998-99) set an ADI of 5 mg/kg body weight/day, while JECFA and EFSA set it at 15 mg/kg/day, and EFSA's comprehensive February 2026 re-evaluation reaffirmed that ADI and concluded it is safe at currently authorised uses. The weight of human evidence finds no clear carcinogenic, reproductive, or neurological harm at typical intakes, but reassurance is tempered by emerging signals: an RCT showing person-specific microbiome-mediated glycemic effects, observational cohort associations with cancer, and 2023 in-vitro genotoxicity of the manufacturing impurity sucralose-6-acetate.

Purported Benefits

✓Zero-calorie sweetness (~600x sweeter than sucrose; contributes negligible energy)
✓No meaningful acute glycemic or insulin response in most people (not metabolized for energy)
✓Exceptional heat stability vs. aspartame, so it can be used in baking and cooking
✓Long shelf life and stability across a wide pH range
✓Does not promote dental caries (non-cariogenic)
✓Enables sugar reduction in foods/beverages for people managing weight or diabetes

Dosing & Compounds

Typical Dose
Approved food additive. FDA ADI 5 mg/kg body weight/day (approved 1998 in 15 food categories, 1999 as a general-purpose sweetener). JECFA (1991) and EFSA ADI 0-15 mg/kg/day, derived from a rodent NOAEL of 1500 mg/kg/day with a 100-fold safety factor; EFSA's February 2026 re-evaluation reaffirmed the 15 mg/kg/day ADI and found EU exposure below it in all population groups. For a 70 kg adult the FDA ADI ≈ 350 mg/day (roughly the amount in several diet beverages).
Active Compounds
E955 (EU/Codex E-number)Brand names: Splenda, Sucraplus, Zerocal, SucraNetDiet/zero soft drinks, flavored waters and sports drinksTabletop sweetener packets and blends (often bulked with maltodextrin/dextrose)Sugar-free gum, candy, baked goods, dairy and frozen desserts, syrupsChewable/liquid medicines, supplements, and protein powders

Safety & Cautions

Major regulators (FDA, EFSA 2026, JECFA, WHO) consider sucralose safe at the ADI, and it shows no consistent evidence of carcinogenicity, genotoxicity, or reproductive/neurological harm in the >110 studies FDA reviewed. Signals under active study: (1) sucralose-6-acetate, a manufacturing impurity/intestinal-digestion product present at up to ~0.67% in commercial sucralose, tested genotoxic (clastogenic) in vitro (Schiffman 2023) — relevance to real-world human exposure is debated and unconfirmed in vivo; (2) a 2022 randomized trial (Suez/Cell) found sucralose and saccharin can impair glucose tolerance in a person-specific, gut-microbiome-dependent manner even below the ADI; (3) the NutriNet-Santé cohort linked higher artificial-sweetener intake to modestly increased cancer risk (strongest for aspartame, observational only); and (4) EFSA 2026 flagged unresolved uncertainty about possible chlorine transfer to organic molecules when sucralose is heated for prolonged periods at high temperature. WHO's 2023 guideline conditionally advises against using non-sugar sweeteners (including sucralose) for weight control, citing no long-term body-fat benefit and possible associations with type 2 diabetes, cardiovascular disease, and mortality. People relying on sucralose for weight loss should not assume benefit; otherwise no specific group is contraindicated at normal intakes. Educational only — always check with your doctor or pharmacist before combining Sucralose with any medicine.

Key Studies ★ 14 studies

guideline / systematic review WHO 2023 ✓ Source
WHO conditionally recommends against using non-sugar sweeteners (incl. sucralose) for weight control, finding no long-term body-fat benefit and possible links to type 2 diabetes, CVD, and mortality.
regulatory EFSA ANS Panel 2026 ✓ Source
EFSA's comprehensive re-evaluation reaffirmed the ADI of 15 mg/kg bw/day and concluded sucralose (E955) is safe at currently authorised uses, with EU exposure below the ADI in all groups; could not confirm safety of new high-temperature baking uses.
regulatory US FDA ✓ Source
FDA determined sucralose safe based on review of >110 studies (no carcinogenic, reproductive, or neurologic risk), approving it in 1998-99 with an ADI of 5 mg/kg bw/day.
systematic review Magnuson et al. 2017 ✓ PubMed
Critical review of the sucralose safety literature concluded available human and animal data support its safety at current intake levels and the established ADI.
RCT Flad 2026 ✓ PubMed
Randomised study finding erythritol, sucrose, and sucralose produce similar reward responses after flavour-preference learning.
RCT Smeets 2026 ✓ PubMed
Randomized crossover study of brain and physiological responses to flavored waters sweetened with different sweeteners.
RCT Chakravartti / Page 2025 ✓ Source
Randomized crossover trial in 75 adults found sucralose vs sucrose increased hypothalamic blood flow and hunger and altered hypothalamic connectivity to reward/motivation regions, with effects varying by sex, body fat, and insulin resistance.
RCT Suez et al. (Cell) 2022 ✓ PubMed
In 120 healthy adults, 2 weeks of sub-ADI sucralose (and saccharin) significantly impaired glycemic responses and altered gut/oral microbiomes; microbiome transplant to germ-free mice reproduced the effect.
in vitro / toxicology Schiffman et al. 2023 ✓ Source
Sucralose-6-acetate (a manufacturing impurity and gut-digestion product, up to ~0.67% of commercial sucralose) was genotoxic/clastogenic in MultiFlow and micronucleus assays and induced gut 'leaky' and inflammatory gene changes.
Review Li 2026 ✓ PubMed
Review of non-nutritive sweeteners, the gut microbiome, and tumour immunity, centred on sucralose.
Review Ivanova 2026 ✓ PubMed
Overview of synthetic sweeteners' health risks, vulnerable populations, and effects on key biological systems.
Review Xin 2026 ✓ PubMed
Effects of Non-Nutritive Artificial Sweeteners on Gut Microbiota and Host Metabolism and Health-Related Outcomes: A Review
Review Sucralose genomic-stress review 2025 ✓ Full text
Review synthesizing environmental persistence, oxidative-stress, and genomic-stress evidence for sucralose, contextualizing the sucralose-6-acetate genotoxicity findings and gut-microbiome and metabolic concerns.
prospective cohort Debras et al. (NutriNet-Santé) 2022 ✓ Source
Among 102,865 French adults, higher artificial-sweetener intake was associated with increased overall cancer risk (HR for higher vs no consumers ~1.13), with the strongest signal for aspartame; observational design limits causal inference.
14 sources cited · 14 verified Search all studies on PubMed ↗

Common questions about Sucralose

What is Sucralose used for?

Sucralose is most often taken for Zero-calorie sweetness (~600x sweeter than sucrose; contributes negligible energy), No meaningful acute glycemic or insulin response in most people (not metabolized for energy), Exceptional heat stability vs. aspartame, so it can be used in baking and cooking, Long shelf life and stability across a wide pH range. The heat-stable, calorie-free chlorinated sugar in Splenda

Does Sucralose work — what does the evidence say?

Moderate evidence. Several controlled trials; effects real but modest or context-dependent. Sucralose (E955, sold as Splenda) is a chlorinated derivative of sucrose roughly 600 times sweeter than sugar, used as a zero-calorie, heat-stable sweetener in diet sodas, tabletop packets, baked goods, dairy, and "sugar-free" and pharmaceutical products. It is approved as a food additive worldwide; the FDA (1998-99) set an ADI of 5 mg/kg body weight/day, while JECFA and EFSA set it at 15 mg/kg/day, and EFSA's comprehensive February 2026 re-evaluation reaffirmed that ADI and concluded it is safe at currently authorised uses. The weight of human evidence finds no clear carcinogenic, reproductive, or neurological harm at typical intakes, but reassurance is tempered by emerging signals: an RCT showing person-specific microbiome-mediated glycemic effects, observational cohort associations with cancer, and 2023 in-vitro genotoxicity of the manufacturing impurity sucralose-6-acetate.

What is the typical dose of Sucralose?

Approved food additive. FDA ADI 5 mg/kg body weight/day (approved 1998 in 15 food categories, 1999 as a general-purpose sweetener). JECFA (1991) and EFSA ADI 0-15 mg/kg/day, derived from a rodent NOAEL of 1500 mg/kg/day with a 100-fold safety factor; EFSA's February 2026 re-evaluation reaffirmed the 15 mg/kg/day ADI and found EU exposure below it in all population groups. For a 70 kg adult the FDA ADI ≈ 350 mg/day (roughly the amount in several diet beverages).

Is Sucralose safe? Any cautions or side effects?

Major regulators (FDA, EFSA 2026, JECFA, WHO) consider sucralose safe at the ADI, and it shows no consistent evidence of carcinogenicity, genotoxicity, or reproductive/neurological harm in the >110 studies FDA reviewed. Signals under active study: (1) sucralose-6-acetate, a manufacturing impurity/intestinal-digestion product present at up to ~0.67% in commercial sucralose, tested genotoxic (clastogenic) in vitro (Schiffman 2023) — relevance to real-world human exposure is debated and unconfirmed in vivo; (2) a 2022 randomized trial (Suez/Cell) found sucralose and saccharin can impair glucose tolerance in a person-specific, gut-microbiome-dependent manner even below the ADI; (3) the NutriNet-Santé cohort linked higher artificial-sweetener intake to modestly increased cancer risk (strongest for aspartame, observational only); and (4) EFSA 2026 flagged unresolved uncertainty about possible chlorine transfer to organic molecules when sucralose is heated for prolonged periods at high temperature. WHO's 2023 guideline conditionally advises against using non-sugar sweeteners (including sucralose) for weight control, citing no long-term body-fat benefit and possible associations with type 2 diabetes, cardiovascular disease, and mortality. People relying on sucralose for weight loss should not assume benefit; otherwise no specific group is contraindicated at normal intakes.

How many studies support Sucralose?

NutriDex cites 14 sources for Sucralose, graded "Moderate".

Cite this page
APA

Peh, D. (2026). Sucralose (E955 · Splenda): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 16 Sept 2026, from https://nutridex.info/s/sucralose

BibTeX
@misc{nutridex_sucralose,
  author       = {Peh, Daryl},
  title        = {Sucralose (E955 · Splenda): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/sucralose},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-09-16}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances